Instil Bio to Present at Jefferies Cell and Genetic Medicine Summit
19 Septembre 2022 - 1:20PM
Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage
biopharmaceutical company focused on developing tumor infiltrating
lymphocyte, or TIL, therapies for the treatment of patients with
cancer, today announced that company management will participate in
an upcoming investor conference:
Jefferies Cell and Genetic Medicine
SummitCompany presentation and Q&A: Thursday,
September 29, 2022 at 10:30 a.m. ET
A live webcast, if recorded, of the presentation can be accessed
under “News & Events” in the Investors section of the Company’s
website at www.instilbio.com. The archived webcast will be
available on the Company’s website shortly after the event.
About Instil BioInstil Bio, Inc. (Nasdaq: TIL)
is a clinical-stage biopharmaceutical company focused on developing
tumor infiltrating lymphocyte, or (TIL), therapies for the
treatment of patients with cancer. The Company has assembled an
accomplished management team with a successful track record in the
development, manufacture, and commercialization of cell therapies.
Using the Company’s proprietary, optimized, and scalable
manufacturing processes at its in-house manufacturing facilities,
Instil is advancing its lead TIL product candidate, ITIL-168, for
the treatment of advanced melanoma and other solid tumors as well
as ITIL-306, a next-generation, genetically engineered TIL therapy
for multiple solid tumors. For more information visit
www.instilbio.com and LinkedIn.
Contacts:Investor
Relations1-972-499-3350investorrelations@instilbio.comwww.instilbio.com
Janhavi MohiteStern Investor
Relations1-212-362-1200janhavi.mohite@sternir.com
Instill Bio (NASDAQ:TIL)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Instill Bio (NASDAQ:TIL)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024